

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

9

Docket No.: 63628(46342)

REMARKS

Claims 1-6 and 12 are pending and are the subject of prosecution for this application. Claims 7-11 and 13-47 are withdrawn for pertaining to a non-elected invention or species.

No new matter has been added by this amendment.

Applicants respectfully reserve the right to pursue any non-elected, canceled or otherwise unclaimed subject matter in one or more continuation, continuation-in-part, or divisional applications.

It is submitted that the claims, herewith and as originally presented were in full compliance with the requirements of 35 U.S.C. § 112. The amendment of the claims, as presented herein, is not made for purposes of patentability within the meaning of 35 U.S.C. §§ 101, 102, 103 or 112. Rather, this amendment is made simply for clarification and to round out the scope of protection to which Applicants are entitled. Furthermore, it is explicitly stated that the herewith amendment should not give rise to any estoppel.

Reconsideration and withdrawal of the rejections of this application in view of the amendments and remarks herewith, is respectfully requested, as the application is in condition for allowance.

Applicant now turns to comments made by the Examiner in this Office Action as follows.

OFFICE ACTION

1. The Examiner states, "The information disclosure statement (IDS) submitted on 2/14/2008 and 6/23/2005 includes non-patent literature citations missing the author, title and/or date. These citations were not considered. The IDS must be amended to include the title, date and author of each non-patent literature reference."

Applicants are submitting an Information Disclosure Statement concurrently which properly cites the title, date and author of each non-patent literature reference.

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

10

Docket No.: 63628(46342)

2. The Examiner states, "The use of the trademark TWEEN-80 has been noted in this application. It should be capitalized wherever it appears and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks."

Applicants have amended the specification to refer to the trademark in a non-generic, proprietary manner using all capitalized letters.

3. The claims are objected to because the lines are crowded too closely together, making reading difficult. Substitute claims with lines one and one-half or double spaced on good quality paper are required. See 37 CFR 1.52(b).

Claims 1-6 and 12 are objected to because of the following informalities: the use of parenthetical and bracketed phrases in the claims is confusing, for example, the bracket following formula I in claim 1. Appropriate correction is required.

With the exception of claim one which has been significantly amended, all other claims have been withdrawn or canceled, thereby obviating the basis for objection. Also, the bracket in claim 1 has been deleted, thereby obviating the basis for that objection.

4. 35 USC § 112 Rejections

The Examiner states, "The genus encompassed by formula I includes countless species and is not characterized by a common core that can be readily envisaged from this chemical formula. At best, several broad subgenera with characteristic backbone structures can be identified. For example, the embodiments wherein Z₂, Z₄, Z₆, Z₈, Z₉ and Z₁₀ are O, Z₁, Z₃, Z₅ and Z₇ are H, Y is -CONH-, Q₂ is CH₂, Y₁, Y₂ and Y₃ are -CON(J₁₃)- and J₁₃ is H, have a peptide backbone. In these compounds, R₁-R₄ and Q₁, Q₁₂ represent side chains. Owing to the broad definition of R₁-R₄ and Q₁-Q₁₂ in claim 1, the peptide sequences included in formula I are not limited to the 20 naturally occurring amino acids, but rather encompass a broad range of natural and non-natural amino

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

11

Docket No.: 63628(46342)

acids. The derivatives are 6, 10, 9, 8 and 7 amino acid residues in length when P is H, II, III, IV and V, respectively. Given the variable side chains and variable backbone lengths, there are countless species encompassed in the peptide subgenera of formula I. Furthermore, the genus encompasses diverse modifications at the N-terminus (J_1 and J_2). Alternatively, the backbone of the compounds of formula I may not be a peptide. For example, if Z_2 , Z_4 , Z_6 , Z_8 , Z_9 and Z_{10} are S, Y is $-\text{CSNH}-$, $-\text{CH}_2\text{NH}-$, $\text{NHCO}-$, $-\text{CH}_2\text{O}-$, $\text{CH}_2\text{S}-$ or $-\text{CH}_2\text{CH}_2-$, Q_2 is NH or O, or Y_1 , Y_2 and Y_3 are $-\text{CSN}(J_{13})-$, $-\text{C}(J_{14})\text{N}(J_{13})-$, or $\text{N}(J_{13})\text{CO}-$, the derivatives have a non-peptide backbone. Any combination of options for each of these variables is permitted creating countless backbones with countless side chains.

The USPTO provides claim terms with their broadest reasonable interpretations in light of the specification. As described above, the term "metastin derivative" in claim 1 is structurally defined in the specification as being represented by formula (I). In addition, the specification limits the genus with functional properties. Paragraph 0375 of the instant specification states that metastin derivatives possess a cancer metastasis suppressing activity or a cancer growth suppressing activity. Claim 5 is limited to agents for suppressing cancer metastasis or proliferation, claim 6 is limited to an agent for treating/preventing cancer and claim 12 is limited to an agent for preventing/treating hormone-dependent cancer.

Claims 1, 3-6 and 12 fail to comply with the written description provision of 35 U.S.C. 112, first paragraph, because while the specification recites a chemical formula to define the structure of the genus, it does not correlate the structure to function and in failing to do so, does not describe a genus of compounds that meet both the structural and functional limitations of the claim, in light of the unpredictability and level of skill in the art. That is, while one of skill in the art could conclude that Applicant was in possession of all of the compounds of formula 1 at the time of filing, one could not conclude that Applicant was in possession of the full scope of compounds that meet the structural requirements of formula I and have the functional ability to suppresses cancer

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

12

Docket No.: 63628(46342)

metastasis or cancer growth or to treat and/or prevent cancer. The structural and functional limitations must both be described to demonstrate possession of the genus of metastin derivatives. In other words, while it is possible for one of skill in the art to easily recognize whether or not they are in possession of a compound having the structure of formula I, it is not possible for one of skill in the art to easily determine, in light of the specification and the knowledge and skill in the art at the time of filing, whether or not they are in possession of a metastin derivative having the structure of formula I, a metastin derivative being a compound of formula I having an ability to suppress cancer metastasis or cancer growth. The rejection is further outlined below.

In addition claims 1, 3-6 and 12 fail to comply with the enablement provision of 35 U.S.C. 112, first paragraph, because while the specification is enabling for the use of metastin derivatives recited in Tables 1-10 for suppressing cancer metastasis and growth and for treating cancer, it is not enabled for the use of the entire scope of compounds encompassed by formula I or for preventing cancer. Given the state of the prior art at the time of filing, the level of skill in the art, the level of unpredictability in the art, and the lack of guidance in the specification on how to identify active embodiments of formula I, the skilled artisan would not be able to use the full scope of the claim without undue experimentation. The rejection is further outlined below.

Claims 1, 3-6 and 12 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The factors to be considered are the scope of the claims discussed above and the following:

Actual Reduction to Practice

Compounds 305 and 322, two embodiments of the claimed invention, were actually reduced to practice at the time of filing. The compounds recited in Tables 1-10

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

13

Docket No.: 63628(46342)

were synthesized and assayed for binding properties characteristic of metastin. All of the compounds in Tables 110 have peptide backbones and comprise 10 amino acid residues. No compounds having a non-peptide backbone were synthesized. With respect to the functional property of treating cancer, compounds 305, 232, 206, 303, 322 and 141 were assayed for cell growth inhibition activity in hot7t175-expressed cho cells *in vitro*, and compounds 305 and 322 were evaluated for anti-tumor activity *in vivo* using tumor-bearing mice with human colonic carcinoma-derived cell line SW620.

Disclosure of Drawings or Structural Chemical Formulas

The specification presents formula (I). The specification fails to correlate this structural formula to function and to identify a common core for the genus that is responsible for the claimed function of metastin derivatives.

Relevant Identifying Characteristics of the Genus

Complete structure: The specification presents generic formula I and specifically the compounds in Tables 1-10 as complete structures of metastin derivatives. All of the compounds in Tables 1-10 have peptide backbones, comprise 10 amino acid residues, and are derivatives of the MS 10 sequence YNWNSFGLRFNH₂ (residues 45-54 of the naturally occurring metastin protein) wherein a substitution or chemical modification is made at 1-5 positions and/or at the N-terminus. No peptide sequences other than these derivatives of MS 10 are presented. No compounds having a non-peptide backbone are presented.

Partial Structure: The specification does not present partial structures of metastin derivatives.

Physical and/or chemical properties: The specification does not describe physical and/or chemical properties of metastin derivatives possessing an ability to treat and/or prevent cancer that would allow a skilled artisan to distinguish compounds that meet only the structural requirements of formula I from compounds that meet both the

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

14

Docket No.: 63628(46342)

structural requirements of formula I and the functional requirements of the definition for metastin recited in the specification.

Structure/Function Correlation: The specification does not describe a correlation between the structure of formula I and the functional property of metastin derivatives to suppress cancer metastasis and growth and to treat and/or prevent cancer. Although the specification presents *in vitro* binding data on a large number of compounds, the compounds are not representative of the entire genus. Furthermore, the specification fails to analyze the data to correlate structure and function. Accordingly, the specification fails to provide guidance on the specific structural features of the genus that account for the function of the genus, namely an ability to treat or prevent cancer. Absent this information, the skilled artisan cannot readily envisage specific embodiments of formula I that possess the claimed functional properties. The skilled artisan can not for example read the specification and readily decipher which positions in formula I are critical for function and which can be changed and in what way to preserve function. The lack of this description limits the ability of the skilled artisan to determine whether or not they are in possession of a species of the claimed genus.

Method of Making the Claimed Compounds

Methods of peptide synthesis are routine in the prior art. Methods of determining which peptide sequence to synthesize in order to satisfy both the structural and functional limitations of the claims are not routine.

Level of Skill and Knowledge in the Art

It is not within the skill of those in the art to design peptide with a desired function or to predictably modify the structure of a peptide to alter the function. It is further not within the skill of those in the art at the time the invention was filed to treat or prevent cancer or to suppress cancer metastasis using metastin or metastin derivatives.

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

15

Docket No.: 63628(46342)

Predictability in the Art

The level of unpredictability in the cancer treatment and prevention art is high. Literature from around the filing date of the instant application describes metastin (also referred to as KISS1) as having a substantiated physiological role in metastasis suppression but does not identify metastin as a therapeutic target or means. Harms *et al.* ("KISS1 metastasis suppression and emergent pathways," *Clinical and Experimental Metastasis*, 2003, 20, 11-18) write:

Metastatic disease is the most critical impediment to cancer patient survival. However, comparatively little is known concerning the intricate pathways which govern the complex phenotypes associated with metastasis. The KISS1 metastasis suppressor gene inhibits metastasis in both *in vivo* melanoma and breast carcinoma models. Despite its clear physiological activity, the mechanism of KISS1 remains unclear. Recent identification of a 54 amino acid peptide of KISS1, termed metastin or kisspeptin-54, and its cognate G-protein coupled receptor (hOT7T175, AXOR12, GPR54) have provided additional clues and avenues of research. While studies have attributed KISS1 with modulation of NFκB regulation, experiments with metastin and its receptor implicate MAP kinase pathways and also suggest the potential of autocrine, paracrine and endocrine roles. Impacts on motility, chemotaxis, adhesion and invasion have each been documented in disparate cell lines and conflicting observations require resolution. Nevertheless, mounting clinical evidence, particularly the loss of KISS1 in metastases, correlates KISS1 and metastin receptor expression with human tumor progression. Together, the data substantiate roles for these molecules in metastasis regulation.

The post-filing date art speculates that metastin is a therapeutic target but has not substantiated this claim. Masui *et al.*, ("Metastin and its variant forms suppress migration of pancreatic cancer cells," *Biochem. Biophys. Res. Com.*, 2004, 315, 85-92) write:

Metastin, a post-translationally modified variant of KISS1, was recently identified as an endogenous peptide agonist for a novel G-protein coupled receptor, hOT7T175 (AXOR12, GPR54). In this study, we analyzed the role of KISS1 and hOT7T175 in both pancreatic cancer tissues and

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

16

Docket No.: 63628(46342)

pancreatic cancer cell lines. Furthermore, we synthesized novel short variant forms of metastin and tested the inhibitory effect of those variants on in vitro cell functions that are relevant to metastasis. Pancreatic cancer tissues showed significantly lower expression of KiSS1 mRNA than normal tissues ($p=0.018$), while cancer tissues showed significantly higher expression of hOT7T175 mRNA than normal pancreatic tissues ($p=0.027$). In human pancreatic cancer cell lines, KiSS1 mRNA was highly expressed in 2 out of 6 pancreatic cancer cell lines, while hOT7T175 mRNA was expressed in all cell lines at various degrees. PANC-1 cells showed the highest expression of hOT7T175. Exogenous metastin did not suppress cell proliferation but significantly reduced the in vitro migration of PANC-1 cells ($p<0.01$). Metastin induced activation of ERK1 in PANC-1 and AsPC-1 cells. Finally, we synthesized 3 novel short variant forms of metastin, FM053a2TFA, FM059a2TFA, and FM052a4TFA. These metastin variants significantly suppressed the migration of PANC-1 cells and activated ERK1. These data suggest that the metastin receptor, hOT7T175, is one of the promising targets for suppression of metastasis, and that small metastin variants could be an anti-metastatic agent to pancreatic cancer.

In summary, there is a lack of evidence in the prior art that metastin can be used to suppress cancer growth or metastasis and treat/prevent cancer, and there is a merely speculative discussion in the post-filing date art that metastin is a therapeutic target. Therefore, the skilled artisan could not use the knowledge of the art at the time the instant application was filed to determine or not they were in possession of a metastin derivative as claimed, that is whether not a compound having a structure of formula I would also have the functional ability to suppress cancer growth or metastasis or treat/prevent cancer. In the absence of guidance in the prior art, guidance in the specification is required and is, as discussed above, insufficient to determine possession.

When the above factors are weighed, one of ordinary skill in the art would not recognize that Applicant was in possession of the claimed genus of metastin derivatives at the time of filing. The compounds presented in Tables 1-10, which are all derivatives of the MS10 peptide, are not representative of the entire genus of formula I which includes peptides of different lengths and non-peptide compounds. Furthermore, the

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

17

Docket No.: 63628(46342)

compounds presented in Tables 1-10 are not representative of the entire sub-genus of peptide compounds of formula I in light of the breadth of the sub-genus, the lack of structure/function correlation presented in the specification and the level of skill and unpredictability in the peptide design and cancer treatment and prevention art. Only the compounds recited in Tables 1-10 meet the written description requirement of 35 U.S.C. 112, first paragraph.

Claims 1, 3-6 and 12 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making and using metastin derivatives recited in Tables 1-10 of the specification, does not reasonably provide enablement for making and using the entire scope of the genus encompassed by formula I. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. The factors considered as set forth in *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) are addressed as follows:

The Nature of the Invention and the breadth of the claims

The claims are drawn to metastin derivatives of formula I. The breadth of the claims were outlined above.

The State of the Prior Art

Literature from around the filing date of the instant application describes metastin (also referred to as KISS1) as having a substantiated physiological role in metastasis suppression but does not identify metastin as a therapeutic target or means. Harms *et al.* ("KISS1 metastasis suppression and emergent pathways," *Clinical and Experimental Metastasis*, 2003, 20, 11-18) write:

Metastatic disease is the most critical impediment to cancer patient survival. However, comparatively little is known concerning the intricate pathways which govern the complex phenotypes associated with metastasis. The KISS1 metastasis suppressor gene inhibits metastasis in

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

18

Docket No.: 63628(46342)

both *in vivo* melanoma and breast carcinoma models. Despite its clear physiological activity, the mechanism of KISS1 remains unclear. Recent identification of a 54 amino acid peptide of KISS1, termed metastin or kisspeptin-54, and its cognate G-protein coupled receptor (hOT7T175, AXOR12, GPR54) have provided additional clues and avenues of research. While studies have attributed KISS1 with modulation of NF κ B regulation, experiments with metastin and its receptor implicate MAP kinase pathways and also suggest the potential of autocrine, paracrine and endocrine roles. Impacts on motility, chemotaxis, adhesion and invasion have each been documented in disparate cell lines and conflicting observations require resolution. Nevertheless, mounting clinical evidence, particularly the loss of KISS1 in metastases, correlates KISS1 and metastin receptor expression with human tumor progression. Together, the data substantiate roles for these molecules in metastasis regulation.

The prior art does not report the structures of metastin derivatives that can be used to suppress cancer metastasis or growth or treat/prevent cancer.

The Predictability or Unpredictability of the Art

The post-filing date art speculates that metastin is a therapeutic target but has not substantiated this claim. Masui *et al.*, ("Metastin and its variant forms suppress migration of pancreatic cancer cells," *Biochem. Biophys. Res. Comm.*, 2004, 315, 85-92) write:

Metastin, a post-translationally modified variant of KISS1, was recently identified as an endogenous peptide agonist for a novel G-protein coupled receptor, hOT7T175 (AXOR12, GPR54). In this study, we analyzed the role of KISS1 and hOT7T175 in both pancreatic cancer tissues and pancreatic cancer cell lines. Furthermore, we synthesized novel short variant forms of metastin and tested the inhibitory effect of those variants on *in vitro* cell functions that are relevant to metastasis. Pancreatic cancer tissues showed significantly lower expression of KISS1 mRNA than normal tissues ($p=0.018$), while cancer tissues showed significantly higher expression of hOT7T175 mRNA than normal pancreatic tissues ($p=0.027$). In human pancreatic cancer cell lines, KISS1 mRNA was highly expressed in 2 out of 6 pancreatic cancer cell lines, while hOT7T175 mRNA was expressed in all cell lines at various degrees. PANC-1 cells showed the highest expression of hOT7T175. Exogenous metastin did not suppress

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

19

Docket No.: 63628(46342)

cell proliferation but significantly reduced the in vitro migration of PANC-1 cells ($p < 0.01$). Metastatin induced activation of ERK1 in PANC-1 and AsPC-1 cells. Finally, we synthesized 3 novel short variant forms of metastatin, FM053a2TFA, FM059a2TFA, and FM052a4TFA. These metastatin variants significantly suppressed the migration of PANC-1 cells and activated ERK1. These data suggest that the metastatin receptor, hOT7T175, is one of the promising targets for suppression of metastasis, and that small metastatin variants could be an anti-metastatic agent to pancreatic cancer.

Jiang *et al.* ("KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha," *Clinical and Experimental Metastasis*, 2005, 22, 369-376) write:

Metastasis is a vital target for cancer treatment, since the majority of cancer patients die from metastatic, rather than the primary disease. *KiSS1* has been identified as a metastasis suppressor gene in melanoma and breast carcinomas. We show here that *KiSS1* is also a metastasis suppressor in human ovarian cancer. Overexpression of *KiSS1* in ovarian cancer cells inhibits cell migration induced by serum or lysophosphatidic acid (LPA), and colonization in soft agar, but not cell proliferation, representing the characteristics of a metastasis suppressor gene. Furthermore, using an experimental metastatic mouse model, we show that expression of *KiSS1* in SKOV3 ovarian cancer cells suppresses >50% metastatic colonization in mice ($P < 0.0001$). We find that activating protein kinase C (PKC) reverses about 80% of the inhibited cell migration induced by *KiSS1*, while down-regulation of PKC α with shRNA restores *KiSS1* effect, providing evidence that inhibiting PKC α may be an important mechanism of the effect of *KiSS1*. These results suggest that *KiSS1* is a metastasis suppressor of ovarian cancer and may be a potential molecular target for the treatment.

Nash *et al.* ("The KISS1 metastasis suppressor: mechanistic insights and clinical utility," *Front. Biosci.*, 2006, 11, 647-59) write:

We were the first to show that the introduction of *KISS1* into highly metastatic human melanoma cell lines C8161 and MelJuSo suppressed metastases to the lung by >95% following intravenous or orthotopic injection (8,9, 33). Interestingly, introduction of *KISS1* into a metastatic breast cancer cell line MDA-MB-435 also showed a >95% suppression of

BOS2 709140 1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

20

Docket No.: 83628(46342)

metastases to the lung following orthotopic injection (33). Those data strongly suggested *KISS1* metastasis suppression may be pertinent in tumors of widely different origins, a conclusion borne out in subsequent studies (11,30,37-40), albeit of varying quality and significance. In general, loss or reduction of *KISS1* expression in several different tumor types inversely correlates with tumor progression, metastatic potential and survival. The data summarized below highlights the potential value of *KISS1* as an important clinical target for the prognostication and treatment of metastatic disease.

Despite many of the unresolved questions, *KISS1* remains a promising molecular target for the treatment of metastatic disease and has shown great promise as a prognostic indicator for several cancers. However, greater efforts need to be made in the characterization of *KISS1* metastasis suppression before its clinical value can be determined.

In summary, there is a lack of evidence in the prior art that metastatin can be used to suppress cancer growth or metastasis and treat/prevent cancer, and there is a merely speculative discussion in the post-filing date art that metastatin is a therapeutic target. Therefore, the skilled artisan could not use the knowledge of the art at the time the instant application was filed to predict whether or not a compound having a structure of formula I would also have the functional ability to suppress cancer growth or metastasis or treat/prevent cancer. In the absence of guidance in the prior art, guidance in the specification is required and is, as discussed below, insufficient to determine allow for predictable use of the claimed compounds.

The Relative Skill of Those in the Art

Methods of peptide synthesis are routine in the prior art. Methods of determining which peptide sequence to synthesize in order to satisfy both the structural and functional limitations of the claims are not routine. It is not within the skill of those in the art to design peptide with a desired function or to predictably modify the structure of a peptide to alter the function. It is further not within the skill of those in the art at the time

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

21

Docket No.: 63628(46342)

the invention was filed to treat or prevent cancer or to suppress cancer metastasis using metastin or metastin derivatives.

The Amount of Direction or Guidance Presented

The specification presents generic formula I and specifically the compounds in Tables 1-10 as examples of metastin derivatives. All of the compounds in Tables 1-10 have peptide backbones, comprise 10 amino acid residues, and are derivatives of the MS10 sequence YNWNSFGLRFNH₂ (residues 45-54 of the naturally occurring metastin protein) wherein a substitution or chemical modification is made at 1-5 positions and/or at the N-terminus. No peptide sequences other than the compounds of Tables 1-10 which share 5-9 common residues with MS10. No compounds having a non-peptide backbone are presented. The specification does not describe physical and/or chemical properties of metastin derivatives possessing an ability to treat and/or prevent hormone-dependent cancer that would allow a skilled artisan to predict if compounds that meet the structural requirements of formula I also meet the functional requirements of the definition for metastin recited in the specification. The specification does not describe a correlation between the structure of formula I and the functional property of metastin derivatives to suppress cancer metastasis and growth and to treat and/or prevent cancer. Although the specification presents *in vitro* binding data on a large number of compounds, the specification fails to analyze the data in terms of a structure/activity relationship. Accordingly, the specification fails to provide guidance on the specific structural features of the genus that account for the function of the genus, namely an ability to treat cancer. Absent this information, the skilled artisan cannot readily predict if specific embodiments of formula I will also exhibit the claimed functional properties of the genus. The skilled artisan can not for example read the specification and readily decipher which positions in formula I are critical for function and which can be changed and in what way to preserve function. The lack of this guidance limits the ability of the skilled artisan to predict whether or not a compound can be used.

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

22

Docket No.: 63628(46342)

The Presence or Absence of Working Examples

Compounds 305 and 322, two embodiments of the claimed invention, were actually reduced to practice at the time of filing. The compounds recited in Tables 1-10 were synthesized and assayed for binding properties characteristic of metastatin. All of the compounds in Tables 1-10 have peptide backbones and comprise 10 amino acid residues. No compounds having a non-peptide backbone were synthesized. With respect to the functional property of treating cancer, compounds 305, 232, 206, 303, 322 and 141 were assayed for cell growth inhibition activity in hot7t175-expressed cho cells *in vitro*, and compounds 305 and 322 were evaluated for anti-tumor activity *in vivo* using tumor-bearing mice with human colonic carcinoma-derived cell line SW620. The specification is enabled for the use of compounds 305 and 322 because the specification clearly established with experimental *in vivo* data that the compounds are functional. It would be routine for the skilled artisan to select additional species from Tables 1-10 and test in animal models described in the specification for an ability to suppresses cancer metastasis or growth.

In contrast, the working examples provided in the specification are not sufficient to enable the use of the entire scope of formula I. The compounds recited in Tables 1-10 of the specification are closely related to the metastatin peptide that has been studied in the prior art and correlated to a physiological role in metastasis and speculated to be a therapeutic target. The scope of the claims is significantly broader than the scope exemplified by these species. There is nothing in the prior art or the specification to suggest that compounds other than those recited in the tables can be used to as metastatin derivatives.

Furthermore, because the metastatin-related metastasis is only one mechanism by which cancer metastasizes, inhibition of this mechanism can not prevent cancer growth resulting from all other mechanisms. Therefore, the working examples presented in the

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

23

Docket No.: 63628(46342)

specification are insufficient to enable all compounds, including 305 and 322, for use in cancer prevention. *The Quantity of Experimentation Necessary*

Considering the factors above, the skilled artisan would be burdened with undue experimentation in determining if one of the claimed compounds would be effective at suppressing cancer metastasis or growth and treating/preventing cancer. The skilled artisan would be burdened with testing a broad range of compounds of formula I in *in vitro* binding assays. The active compounds would then have to be subjected to animal models of cancer growth and metastasis. The experimentation required represents years of inventive effort. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

Therefore, in view of the *Wands* factors, the claims appear to require undue experimentation to use the full scope of the claimed invention."

Applicants have amended claim 1 to limit it to one specific compound and a salt thereof. Applicants also have withdrawn or canceled all other claims, thereby obviating the basis for rejections under 35 USC § 112.

5. The Examiner states, "Claims 1, 3-6 and 12 are rejected under 35 U.S.C. 102(b) as being anticipated by Stafford *et al.* (*Cancer Research.*, **2002**, 62, 5399-5404, reference CB on Information Disclosure Statement filed 4/14/2008). Stafford *et al.* teach the peptide YNWNSFGLRY (KISS1 peptide, Figure 1). With respect to formula I, P is YNWN (amino acids 45-48 of SEQ ID NO: 1). The amino acid sequence YNWN is consistent with the formula $J^1-J^2-C(J^3)(Q^3)Y^1C(J^4)(Q^4)Y^2C(J^5)(Q^5)Y^3C(J^6)(Q^6)C(=Z^{10})$ - wherein: J^1 , J^3 , J^4 , J^5 and J^6 are H; J^2 is NH; Q^3 is the side chain of tyrosine, a C_1 alkyl group substituted with a C_6 aromatic hydrocarbon group substituted with hydroxyl; Q^4 is the side chain of asparagine, a C_1 alkyl group substituted with an amide group; Q^5 is the side chain of tryptophan, a C_1 alkyl group substituted with a 9-membered aromatic fused heterocyclic group consisting of 8 carbons and 1 nitrogen; Q^6 is the side chain of

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

24

Docket No.: 63628(46342)

asparagine, a C₁ alkyl group substituted with an amide group; Y₁, Y₂ and Y₃ represent -CON(J₁₃)- wherein J¹³ is H; and Z¹⁰ is O. With respect to the remainder of formula I, Z¹, Z³, Z⁷ are H; Z², Z⁴, Z⁶ and Z⁸ are O; R¹ is the side chain of serine, a C₁ alkyl group substituted with hydroxyl; R² is the side chain of leucine, a C₄ alkyl group; R³ is the side chain of arginine, a C₃ alkyl group substituted with a basic group; and R⁴ is the side chain of tyrosine, a C₁ alkyl group substituted with a C₆ aromatic hydrocarbon group substituted with hydroxyl. Finally, with respect to variable X, Q¹ is the side chain of phenylalanine, a C₁ alkyl group substituted with a C₆ aromatic hydrocarbon group; Y is -CONH-; Q₂ is CH₂; and Z⁹ is O. The peptide sequence is not found in SEQ ID NO: 1. Thus, the peptide meets all the structural limitations of claims 1, 3-15 and 38-41.

With respect to claim 3, Stafford *et al.* teach mKiSS1 and hKiSS1, each of which comprise the peptide YNWNSFGLRY. These longer proteins may undergo proteolytic cleavage to yield the 10 amino acid peptide YNWNSFGLRY. Therefore, mKiSS1 and hKiSS1 are prodrugs of the peptide YNWNSFGLRF which is a species of formula I.

With respect to claim 4, Stafford *et al.* teach a composition comprising KiSS1 1 peptide and FBS and LiCl (Materials and Methods page 5401, PLC-β Assay).

With respect to claims 5, 6 and 12, neither Kotani *et al.* or Stafford *et al.* teach that the kisspeptin-10 or KiSS1 peptide can suppress cancer metastasis, suppress cancer proliferation, treat or prevent cancer, or treat or prevent hormone-dependent cancer. Because the chemical structure of the species taught by Kotani *et al.* and Stafford *et al.* are identical to species within the claimed genus, the prior art species inherently meet these additional functional limitations. The discovery and characterization of properties of a known material do not make it novel (see MPEP § 2112). Furthermore, there is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the time of invention, but only that the subject matter is in fact inherent in the prior art reference (see MPEP § 2112). If the composition is physically the same, it must have the same functional properties. A

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

25

Docket No.: 63628(46342)

chemical composition and its properties are inseparable. Because the prior art of Kotani *et al.* and Stafford *et al.* teach the identical chemical structure as the claimed genus, the functional properties applicant claims are necessarily present (see MPEP § 2112.01). Examiner cannot however determine whether or not kisspeptin-10 or KiSS1 peptide taught by Kotani *et al.* and Stafford *et al.*, respectively, inherently possesses properties which anticipate or render obvious the claimed invention but has basis for shifting the burden of proof to applicant. See MPEP § 2112."

Applicants have amended claim 1 to limit it to one specific compound and a salt thereof. Applicants also have withdrawn or canceled all other claims, thereby obviating the basis for rejection under 35 USC § 102.

6. Claims 1, 3-6 and 12 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 6 of copending application 11/977,477. Although the conflicting claims are not identical, they are not patentably distinct from each other because claims 1, 3-6 and 12 are generic to all that is recited in claim 6 of copending application 11/977,477. That is claim 6 of copending application 11/977,477 falls entirely within the scope of claims 1, 3-6 and 12 or, in other words, claims 1, 3-6 and 12 are anticipated by claim 6 of copending application 11/977,477. Specifically, claim 6 of copending application recites:

Ac-D-Tyr-Hyp-Asn-Thr-Cha-Gly-Ala(cPr)-Arg(Me)-Trp-NH₂,

Ac-D-Tyr-Hyp-Asn-Thr-Cha-Glyψ((E)CH=CH)-Leu-Arg(Me)-Trp-NH₂,

Ac-D-Tyr-Hyp-Alb-Thr-Cha-Glyψ((E)CH=CH)-Leu-Arg(Me)-Trp-NH₂,

Ac-D-Tyr-Hyp-Asn-Thr-Cha-Glyψ((E)CH=CH)-Leu-Arg-Trp-NH₂,

Ac-D-Tyr-Hyp-Alb-Thr-Cha-Glyψ((E)CH=CH)-Leu-Arg-Trp-NH₂,

BOS2 709140.1

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

28

Docket No.: 63628(46342)

Ac-D-Tyr-Hyp-Alb-Thr-Cha-Gly-Ala(cPr)-Arg(Me)-Trp-NH₂ and

Ac-D-Tyr-Pro(4F)-Asn-Thr-Cha-Gly-Ala(cPr)-Arg(Me)-Trp-NH₂,

with respect to formula I, Z₂, Z₄, Z₆, Z₈, Z₉ and Z₁₀ are O, Z₁, Z₃, Z₅ and Z₇ are H, Y is -CONH-, Q₂ is CH₂, Y₂ and Y₃ are -CON(J₁₃)-, J₇, J₈, J₉, and J₁₃ are H, and Q₇, Q₈, Q₉, R₁, Q₁, Q₂, R₂, R₃ and R₄ correspond to the side chains of amino acids 1-9, respectively.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1, 3-6 and 12 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 50 of copending application 11/630,698. Although the conflicting claims are not identical, they are not patentably distinct from each other because claims 1, 3-6 and 12 are generic to all that is recited in claim 50 of copending application 11/630,698. That is claim 50 of copending application 11/630,698 falls entirely within the scope of claims 1, 3-6 and 12 or, in other words, claims 1, 3-6 and 12 are anticipated by claim 50 of copending application 11/630,698. Specifically, claim 6 of copending application recites compound 305 and 385 which are identical to those in the instant specification. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicants have amended claim one to one specific compound and salt thereof. Applicants also have withdrawn or canceled all other claims. The compound recited in amended claim 1 is different from the compounds recited in claim 6 of co-pending U. S. application 11/977,477 or compounds recited in claim 50 of co-pending U.S. application 11/630,698. Therefore, the provisional obviousness-type double patenting rejection is obviated.

BOS2 709140.1

RECEIVED
CENTRAL FAX CENTER
DEC - 9 2008

Application No. 10/540,494
Amendment dated December 9, 2008
Reply to Office Action of August 11, 2008

27

Docket No.: 63628(46342)

In view of the above amendment, applicant believes the pending application is in condition for allowance.


FEE AUTHORIZATION

Applicant requests a one-month extension of time to file the within response. The Commissioner is authorized to charge the extension fee and any other fees associated with this submission to our Deposit Account, No. 04-1105, Reference 63628(46342). Any overpayment should be credited to said Deposit Account.

Dated: December 9, 2008

Respectfully submitted,

Customer No. 21874

By 
Gregory B. Butler, Ph.D., Esq.
Registration No.: 34,558
EDWARDS ANGELL PALMER & DODGE
LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 517-5595
Attorneys/Agents For Applicant

BOS2 709140.1